PHAXIAM Therapeutics S.A. EBIT

PHAXIAM Therapeutics S.A. (PHXM) currently reports a EBIT of $-15M as of December 2023. That compares with $-19M in the prior-year period — up 17.4% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore PHAXIAM Therapeutics S.A.'s EBIT history and peer comparisons.

PHAXIAM Therapeutics S.A.'s EBIT increased from $-19M to $-15M — a 17.4% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

PHAXIAM Therapeutics S.A.'s EBIT of $-15M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

PHAXIAM Therapeutics S.A. reported $-15M in EBIT as of December 2023. That compares with $-19M in the prior-year period — up 17.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-15M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for PHAXIAM Therapeutics S.A., and consider following PHXM for alerts when major investors trade the stock.